Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lymphoma: targeted drug shows promise

NCT ID NCT05144841

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called zilovertamab vedotin (MK-2140) in 140 people with diffuse large B-cell lymphoma that had returned or stopped responding to at least two prior treatments. The goal was to see how many patients had their tumors shrink or disappear. The study is now complete, and results will help determine if this drug should move forward in development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zilovertamab vedotin (MK-2140)
What this could lead to
If successful, this could offer a new treatment option for people with aggressive lymphoma that has not responded to prior therapies.
What could go wrong
This is a phase 2 trial with a small number of participants and no comparison group. The drug may not work for everyone and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

140 people

The number who actually took part.

Started

Jan 2022

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has relapsed or refractory (rr) DLBCL; has progressed after at least 2 lines of prior therapy; and has progressed after auto- stem cell transplant (SCT) or are auto-SCT ineligible. Must have received prior multiagent regimen that includes an alkylating agent. anthracycline, and anti-CD20 (cluster of differentiation 20) monoclonal antibody. * Has histologically confirmed diagnosis of DLBCL. * Has radiographically measurable DLBCL per the Lugano Response Criteria. * Should either be post- chimeric antigen receptor T cell therapy (CAR-T) failure or ineligible for CAR-T (for any reason). * Life expectancy of at least 3 months. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before time of enrollment. * Has adequate organ function. Exclusion Criteria: * Has received a diagnosis of Primary mediastinal B-cell lymphoma (PMBCL). * Has undergone solid organ transplant at any time. * Has a history of any clinically significant cardiovascular conditions within 6 months of screening or serious cardiac arrhythmia requiring medication. * Has known history of liver cirrhosis. * Has pericardial effusion or clinically significant pleural effusion. * Has ongoing Grade \>1 peripheral neuropathy. * Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * Transformed DLBCL from indolent lymphoma. * In participants with prior allo-SCT, acute graft versus host disease (GVHD) or ongoing evidence of chronic GVHD. * Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention. * Has received prior radiotherapy within 28 days of start of study intervention. Participants. must have recovered from all radiation-related toxicities. * Has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent). * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. * Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma. * Has an active infection requiring systemic therapy. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known history of hepatitis B or known active hepatitis C virus (HCV).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed or refractory diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed or refractory diffuse large B-cell lymphoma

Contacts and locations

Locations

  • AHN West Penn Hospital ( Site 0212)

    Pittsburgh, Pennsylvania, 15224, United States

  • Ankara University Hospital Cebeci-hematology ( Site 2300)

    Ankara, 06100, Turkey (Türkiye)

  • Atlantic Health System Morristown Medical Center ( Site 0213)

    Morristown, New Jersey, 07960, United States

  • Avera Cancer Institute- Research ( Site 0233)

    Sioux Falls, South Dakota, 57105, United States

  • Beijing Cancer hospital ( Site 2900)

    Beijing, Beijing Municipality, 100142, China

  • Centre Hospitalier de la Côte Basque ( Site 1002)

    Bayonne, Aquitaine, 64109, France

  • Clínica Alemana de Santiago ( Site 2704)

    Santiago, Region M. de Santiago, 7650568, Chile

  • Dokuz Eylül Üniversitesi-Hematology ( Site 2304)

    Izmir, 35340, Turkey (Türkiye)

  • Evangelismos General Hospital of Athens ( Site 1214)

    Athens, Attica, 106 76, Greece

  • Faculty of Medicine Siriraj Hospital ( Site 0701)

    Bangkok, Bangkok, 10700, Thailand

  • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0800)

    Brno, Brno-mesto, 625 00, Czechia

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa di Ematologia ( Site 1501)

    Milan, Lombardy, 20133, Italy

  • Franciscan St. Francis Health ( Site 0225)

    Indianapolis, Indiana, 46237, United States

  • Fudan University Shanghai Cancer Center ( Site 2908)

    Shanghai, Shanghai Municipality, 200032, China

  • General Hospital of Athens "Laiko"-Hematology Department ( Site 1213)

    Athens, Attica, 115 27, Greece

  • Georgetown University Medical Center ( Site 0204)

    Washington D.C., District of Columbia, 20007, United States

  • Hacettepe Universitesi-Department of Hematology ( Site 2302)

    Ankara, 06230, Turkey (Türkiye)

  • Hadassah Medical Center ( Site 1402)

    Jerusalem, 9112001, Israel

  • Haukeland Universitetssjukehus ( Site 1601)

    Bergen, Hordaland, 5021, Norway

  • Henan Cancer Hospital-hematology department ( Site 2903)

    Zhengzhou, Henan, 450008, China

  • Hospital Universitari Vall d'Hebron ( Site 2005)

    Barcelona, 08035, Spain

  • Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 2000)

    Madrid, 28040, Spain

  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca ( Site 2003)

    Salamanca, 37007, Spain

  • Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1503)

    Rozzano, Milano, 20089, Italy

  • Hunan Cancer Hospital ( Site 2905)

    Changsha, Hunan, 410013, China

  • IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1500)

    Bologna, 40138, Italy

  • Innovative Clinical Research Institute ( Site 0202)

    Whittier, California, 90603, United States

  • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 2002)

    L'Hospitalet Del Llobregat, Barcelona, 08908, Spain

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1502)

    Naples, 80131, Italy

  • James Lind Centro de Investigación del Cáncer ( Site 2705)

    Temuco, Araucania, 4800827, Chile

  • Karadeniz Teknik Universitesi Tip Fakultesi-Hematology ( Site 2307)

    Trabzon, 61080, Turkey (Türkiye)

  • Karmanos Cancer Institute ( Site 0216)

    Detroit, Michigan, 48201, United States

  • Karolinska Universitetssjukhuset Solna ( Site 2102)

    Solna, Stockholm County, 171 64, Sweden

  • MEDICAL COLLEGE OF WISCONSIN ( Site 0234)

    Milwaukee, Wisconsin, 53226, United States

  • Maharaj Nakorn Chiang Mai Hospital ( Site 0702)

    Muang, Chiang Mai, 50200, Thailand

  • Massachusetts General Hospital-Cancer Center Protocol Office ( Site 0203)

    Boston, Massachusetts, 02114, United States

  • Mega Medipol-Hematology ( Site 2308)

    Istanbul, 34214, Turkey (Türkiye)

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • New York Medical College ( Site 0215)

    Valhalla, New York, 10595, United States

  • North Estonia Medical Centre Foundation ( Site 0900)

    Tallinn, Harju, 13419, Estonia

  • Northside Hospital ( Site 0206)

    Atlanta, Georgia, 30342, United States

  • Ondokuz Mayıs Universitesi ( Site 2306)

    Samsun, 55139, Turkey (Türkiye)

  • Oslo universitetssykehus, Radiumhospitalet ( Site 1600)

    Oslo, 0310, Norway

  • Pitie Salpetriere University Hospital-Clinical haematology ( Site 1000)

    Paris, 75013, France

  • Pratia Onkologia ( Site 1701)

    Katowice, Silesian Voivodeship, 40-519, Poland

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0100)

    Toronto, Ontario, M5G 2M9, Canada

  • SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal Medicine ( Site 2907)

    Guangzhou, Guangdong, 510030, China

  • Saint Louis University Cancer Center ( Site 0209)

    St Louis, Missouri, 63110, United States

  • Samsung Medical Center ( Site 0600)

    Seoul, 06351, South Korea

  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 0601)

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center ( Site 1404)

    Jerusalem, 9103102, Israel

  • Shanghai East Hospital ( Site 2902)

    Shanghai, Shanghai Municipality, 200120, China

  • Skånes Universitetssjukhus Lund ( Site 2100)

    Lund, Skåne County, 22185, Sweden

  • Soroka Medical Center-Hematology Department ( Site 1403)

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 1400)

    Tel Aviv, 64239, Israel

  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229)

    Orange, California, 92868, United States

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1707)

    Krakow, Lesser Poland Voivodeship, 31-826, Poland

  • Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1702)

    Gdynia, Pomeranian Voivodeship, 81-519, Poland

  • The First Affiliated Hospital, Zhejiang University-Bone marrow transplant centre ( Site 2912)

    Hangzhou, Zhejiang, 310003, China

  • The First Hospital of Jilin University-Hematology ( Site 2910)

    Changchun, Jilin, 130021, China

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C

    Columbus, Ohio, 43210, United States

  • Tianjin Medical University Cancer Institute and Hospital-lymphoma ( Site 2901)

    Tianjin, Tianjin Municipality, 300060, China

  • University Hospitals Cleveland Medical Center ( Site 0222)

    Cleveland, Ohio, 44106, United States

  • University of Chicago Medical Center ( Site 0207)

    Chicago, Illinois, 60637, United States

  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0217)

    Cincinnati, Ohio, 45219, United States

  • University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0211)

    Baltimore, Maryland, 21201, United States

  • University of Michigan ( Site 0200)

    Ann Arbor, Michigan, 48109, United States

  • Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site

    Wroclaw, Lower Silesian Voivodeship, 50-367, Poland

  • Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0801)

    Prague, 12808, Czechia

  • West China Hospital of Sichuan University-Head and Neck Oncology ( Site 2911)

    Chengdu, Sichuan, 610041, China

  • Wuhan Union Hospital ( Site 2906)

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.